<DOC>
	<DOC>NCT02232425</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.</brief_summary>
	<brief_title>IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<criteria>In stable (≥ 6 months) heterosexual relationship Have lifelong (primary) premature ejaculation Have premature ejaculation confirmed by IELT less than or equal to (≤) 1 minute on ≥ 75% attempts at sexual intercourse Meet other aspects of the International Society for Sexual Medicine (ISSM) definition for lifelong PE, including inability to delay ejaculation on all or nearly all vaginal penetrations and negative personal consequences such as distress, bother and frustration Willing to attempt intercourse at least 4 times during runin period and at least 8 more times during doubleblind part of the study Not planning pregnancy with his partner and he is willing to use contraception (unless not of childbearing potential, e.g., surgically sterilised) Willing to limit use of alcohol on days in which they take study drug (not more than three drinks, where one drink is defined as a 12 ounce (oz), 360 milliliter (mL) bottle of beer, a 5 oz (150 mL) glass of wine, or a 1½ oz (45 mL distilled spirits) Capable of giving written informed consent An IELT value ≥ 2 minutes during runin period Less than (&lt;) 4 attempts at sexual intercourse during runin (screening may be extended or patient may be rescreened if there are extenuating circumstances) A rating of control of ejaculation as fair, good, or very good on the PEP questionnaire prior to study Coexisting Erectile Dysfunction International Index of Erectile Dysfunction (IIEF) erectile function domain &lt; 22 during runin Concomitant use of Phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections, penile implants, Selective Serotonin Reuptake Inhibitors (SSRI's) or SerotoninNorepinephrine Reuptake Inhibitors (SSNRI's), tricyclic antidepressants (for example (e.g.) clomipramine), monoamine oxidase inhibitors, alpha blockers, 5 alpha reductase inhibitors (including propecia for hair loss), topical anaesthetics, and/or tramadol History (last 6 months) of use of Botox or similar product to treat premature ejaculation Unwilling to stop other treatments for premature ejaculation (including but not limited to pharmacological, herbal, multiple condoms, psychosexual treatment, prior masturbation) Other sexual disorder of patient or partner that could interfere with results Current active sexually transmitted disease Major medical condition of patient that could interfere with ability to have sexual activity and or require hospital treatment Body Mass Index (BMI) &gt; 40 kg/m2 Participation in a clinical drug trial anytime during the 30 days prior to screening Human Immunodeficiency Virus (HIV) or hepatitis B History of clinically significant prostate disease History of myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically evident congestive heart failure, cardiac pacemaker, or cerebrovascular accident Cardiac arrhythmia: significant cardiac arrhythmia shown on Electrocardiogram (ECG), or a known or suspected history of significant cardiac arrhythmias within last six months History of congenital QT prolongation and/ corrected QT (QTc) interval &gt; 450 milliseconds (msec) using the Bazett formula Mean systolic cuff blood pressure (BP) &gt; 140 millimeter of mercury (mmHg), as assessed by up to three measurements taken in sequence within 510 minutes of last measure Mean diastolic cuff BP &gt; 90 mmHg, as assessed by up to three measurements taken in sequence within 510 minutes of the last measure Major psychiatric disease or risk of suicidal tendency as assessed by clinical evaluation and Patient Health Questionnaire (PHQ)9 and Columbia Suicide Assessment PHQ9 questionnaire total score &gt; 9 and/or score &gt; 0 for question 9 of PHQ9, and/or suicidal ideation or behavior as assessed by Columbia Suicide Assessment Clinically significant abnormal laboratory function test results (including liver enzymes &gt; 2 x Upper Limit of Normal (ULN) or bilirubin &gt; 1.5 x ULN) Taking Cytochrome P450 3A4 (CYP3A4) inducers, or moderate and potent CYP3A4 inhibitors</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>